Free Trial
NASDAQ:BCAX

Bicara Therapeutics Q4 2024 Earnings Report

Bicara Therapeutics logo
$11.64 +0.19 (+1.66%)
As of 02:04 PM Eastern

Bicara Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Bicara Therapeutics' Q1 2025 earnings is scheduled for Thursday, June 26, 2025

Remove Ads

Bicara Therapeutics Earnings Headlines

HC Wainwright Expects Lower Earnings for Bicara Therapeutics
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat